No Data
Innovative Bispecific Antibody CT-95 Drives Buy Rating for Context Therapeutics
Context Therapeutics Inc. Announces Preclinical Data Supporting Unique Binding Mechanism of CT-95 and Progress in Phase 1 Clinical Trial
Context Therapeutics Presents New Preclinical Data for Solid Tumor Therapy at Major Cancer Conference
Context Therapeutics Presents Preclinical and Translational Data for CT-95, a Mesothelin Targeting T Cell Engager, at 2025 AACR Annual Meeting
William Blair Maintains Context Therapeutics(CNTX.US) With Buy Rating
Analysts Offer Insights on Healthcare Companies: Context Therapeutics (CNTX) and Align Tech (ALGN)
